These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37369907)

  • 1. Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study.
    Rousseau N; Lebreton O; Masse H; Maucourant Y; Pipelart V; Clement M; Le Lez ML; Khanna RK; Pepin M; Eude Y; Le Meur G; Weber M; Ducloyer JB
    Ophthalmol Ther; 2023 Oct; 12(5):2781-2792. PubMed ID: 37369907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant.
    Baillif S; Staccini P; Weber M; Delyfer MN; Le Mer Y; Gualino V; Collot L; Merite PY; Creuzot-Garcher C; Kodjikian L; Massin P
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE.
    Elbarky AM
    Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Dexamethasone in Diabetic Macular Oedema: A Way of Enhancing the Response to Anti-VEGF in Non- or Poor Responders?
    Touhami S; Dupas B; Bertaud S; Tadayoni R; Couturier A
    Ophthalmologica; 2022; 245(4):350-357. PubMed ID: 34587614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
    Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema.
    Borella Y; Bertaud S; Tadayoni R; Bodaghi B; Dupas B; Touhami S
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38668853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
    Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
    Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
    Elbarky AM
    Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
    McCluskey JD; Kaufman PL; Wynne K; Lewis G
    Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
    [No Abstract]   [Full Text] [Related]  

  • 12. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.
    Soares RM; Ferreira CC; Fernandes JDS; Madeira C; Silva LMA; Saraiva E; Ribeiro L; Fonseca S
    Clin Ophthalmol; 2024; 18():1057-1066. PubMed ID: 38646183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial.
    Mishra SK; Sinha S; Chauhan R; Kumar A
    Curr Drug Deliv; 2021; 18(6):825-832. PubMed ID: 33267762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: The ILUvien in Postoperative CYstoid Macular eDema study.
    Motloch K; Soler V; Delyfer MN; Vasseur V; Wolff B; Issa M; Dot C; Massé H; Weber M; Comet A; Hitzl W; Matonti F; Creuzot-Garcher C; Tadayoni R; Kodjikian L; Couturier A
    Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39004282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results.
    Chronopoulos A; Chronopoulos P; Ashurov A; Korb C; Pfeiffer N; Hattenbach LO
    Eur J Ophthalmol; 2022 Jan; 32(1):443-449. PubMed ID: 33601897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients.
    Dang Y; Mu Y; Li L; Mu Y; Liu S; Zhang C; Zhu Y; Xu Y
    Drug Des Devel Ther; 2014; 8():1441-9. PubMed ID: 25258512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.